Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on July 23, 2024, to announce its financial results for the quarter ended June 30, 2024. The core of this filing is the attached press release (Exhibit 99.1), which provides the company's performance update for the period. Investors should refer to this press release for detailed financial figures, operational performance, and any forward-looking statements or guidance provided by the company. While the 8-K itself is a formal notification of the earnings release, the actual substance of the financial results, including revenue, profitability, and key performance indicators, will be found within the incorporated press release. Investors are encouraged to review Exhibit 99.1 for a comprehensive understanding of Quest Diagnostics' recent financial condition and operational outcomes.
Key Highlights
- 1Quest Diagnostics (DGX) filed an 8-K on July 23, 2024, to report Q2 2024 financial results.
- 2The primary information is contained within the attached press release (Exhibit 99.1).
- 3Investors need to review Exhibit 99.1 for detailed financial performance data.
- 4The filing serves as a formal notification of the company's quarterly earnings announcement.
- 5Key performance indicators and financial metrics for the quarter ended June 30, 2024, are expected in the press release.